Compare Inovio Pharmaceuticals Inc (INO) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Norfolk Southern Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Norfolk Southern Corporation trades at $317.62 (market cap $71.20B). The key difference: Norfolk Southern Corporation is far larger — about 634.6× Inovio Pharmaceuticals Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Norfolk Southern Corporation for 33 Days on average.
| INO | NSC | |
|---|---|---|
Market Cap | $112.19M | $71.20B |
Volume | 3,201,278 | 555,248 |
Sector | Health | Industrials |
52-Week High | $2.65 | $352.98 |
52-Week Low | $0.66 | $278.19 |
Typical Hold Time | 43 Days | 33 Days |
Enterprise Value | $83.51M | $86.75B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Norfolk Southern (NSC) trades at $317.67, up 1.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with a strong net income margin of 21.02% (2026). Positive sentiment surrounds the proposed merger with Union Pacific, which is advancing through regulatory review and is backed by over 500 customers, as reported by Business Wire on September 22, 2026.
The outlook is positive, with a consensus price target of $361.86 offering ~14% upside. Key opportunities include freight share gains from trucking and merger synergies, while risks involve fuel price pressures on margins and regulatory hurdles for the combination. Earnings on October 22, 2026, will be a critical catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
